Recap: Eli Lilly Q2 Earnings

Shares of Eli Lilly LLY moved lower by 2.3% in pre-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share rose 26.00% year over year to $1.89, which beat the estimate of $1.56.

Revenue of $5,499,000,000 declined by 2.45% year over year, which missed the estimate of $5,760,000,000.

Looking Ahead

The upcoming fiscal year's EPS expected to be between $7.20 and $7.40.

The upcoming fiscal year's revenue expected to be between $23,700,000,000 and $24,200,000,000.

How To Listen To The Conference Call

Date: Jul 30, 2020

Time: 09:00 AM

ET Webcast URL: https://edge.media-server.com/mmc/p/9cyavje9

Recent Stock Performance

Company's 52-week high was at $170.75

Company's 52-week low was at $101.36

Price action over last quarter: down 0.19%

Company Description

Eli Lilly is a drug company with a focus on neuroscience, endocrinology, oncology, and immunology. Lilly's key products include Alimta and Verzenio for cancer; Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.